Vera Therapeutics Reports Increased Net Losses of $121M in Q1 2026

Vera Therapeutics, Inc. reported a significant increase in net losses for the first quarter of 2026, amounting to $121.0 million, compared to a net loss of $51.7 million for the same period in 2025. The company's total operating expenses surged to $125.1 million, a 119% increase from $57.2 million year-over-year. This rise was primarily driven by heightened research and development costs, which reached $86.0 million, up 108% from $41.3 million in the prior year. General and administrative expenses also saw a substantial increase, climbing 146% to $39.1 million, reflecting the company's efforts to prepare for potential commercialization of its lead product candidate, atacicept.

In terms of financial position, Vera Therapeutics reported cash, cash equivalents, and marketable securities totaling $596.8 million as of March 31, 2026, a decrease from $714.6 million at the end of 2025. The company’s accumulated deficit increased to $881.9 million, up from $760.9 million at the end of the previous fiscal year. The decline in cash reserves was attributed to substantial cash outflows from operating activities, which totaled $106.5 million for the quarter, compared to $54.4 million in the same quarter of 2025.

Strategically, Vera Therapeutics is focused on advancing its clinical programs, particularly for atacicept, which is being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). The company is currently conducting the pivotal Phase 3 ORIGIN trial, which has shown promising results in reducing proteinuria. Vera has also submitted a Biologics License Application (BLA) for atacicept to the FDA, which has granted priority review with a target action date set for July 7, 2026. The company is also exploring additional indications for atacicept in other autoimmune kidney diseases.

Operationally, Vera Therapeutics has increased its workforce to support its expanding clinical and administrative functions, with a notable rise in employee compensation and related benefits. The company is also investing in external manufacturing capabilities to ensure sufficient supply for clinical trials and potential commercialization. As of March 31, 2026, the company had 71.7 million shares of Class A common stock outstanding, reflecting ongoing efforts to raise capital through equity offerings.

Looking ahead, Vera Therapeutics anticipates continued net losses as it progresses through clinical trials and prepares for potential product launches. The company plans to seek additional funding through equity or debt financing to support its operations and development activities. Management believes that the current cash reserves will be sufficient to fund operations for at least the next 12 months, but acknowledges the need for substantial additional capital to achieve its long-term business objectives.